University of Cologne: Lymphoma trials

The registry lists 26 Lymphoma studies with University of Cologne as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 20Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06919679Phase 2
• Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin LymphomaNot yet recruitingNCT06916416Phase 2
• Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2
• Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2
• Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaRecruitingNCT04837859Phase 2
• TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaTerminatedNCT04161118Phase 2
• Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 TherapyActive, not recruitingNCT03480334Phase 2
• Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2
• HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
• Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)CompletedNCT02626884Phase 2
• GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02321592Phase 2
• Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
• JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
• Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis FungoidesStatus unknownNCT01645293Phase 1
• Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin LymphomaCompletedNCT01569204Phase 2
• Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01453504Phase 1/2
• HD17 for Intermediate Stage Hodgkin LymphomaCompletedNCT01356680Phase 3
• Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma PatientsCompletedNCT01056679Phase 1
• Protection of Ovarian Function in Female Patients With Hodgkin LymphomaCompletedNCT01014507Phase 2
• HD16 for Early Stage Hodgkin LymphomaStatus unknownNCT00736320Phase 3
• HD18 for Advanced Stages in Hodgkins LymphomaCompletedNCT00515554Phase 3
• PVAG-14 Pilot for Intermediate Stages Hodgkin LymphomaTerminatedNCT00512980Phase 2
• Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins LymphomaCompletedNCT00284271Phase 2
• Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's LymphomaTerminatedNCT00148018Phase 2
• Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00147953Phase 2
• Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's LymphomaCompletedNCT00147875Phase 1/2